{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/paronychia-acute/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"17d25ace-76d2-5ab6-ac1d-8a1238ea8e09","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field c1262a83-0dc0-40fb-8374-f825e5737701 --><h2>Erythromycin</h2><!-- end field c1262a83-0dc0-40fb-8374-f825e5737701 -->","summary":"","htmlStringContent":"<!-- begin item 3bbcbdb8-8cd3-42b5-9747-c2674a8c826a --><!-- end item 3bbcbdb8-8cd3-42b5-9747-c2674a8c826a -->","topic":{"id":"b2bb7fc0-a6db-5872-b76f-83f50e0814ee","topicId":"6c8ca646-4291-4610-b32e-02c43d2c8af9","topicName":"Paronychia - acute","slug":"paronychia-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"9d232456-a0db-59c3-81d2-6066b705f267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e855a6e8-ed6f-50da-8601-bb658a2c2142","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b7baf273-3ab9-5b99-91b1-7ff165d7b93e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"118743c0-8ede-55bf-b84a-3f9b8fcebdd8","slug":"changes","fullItemName":"Changes"},{"id":"4ba6812b-5e78-5829-a1ca-8f8a57fe62b4","slug":"update","fullItemName":"Update"}]},{"id":"d477c411-32be-55fe-a86e-08290f4d2b8e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8c33920b-b3ac-508f-b75a-1eff779e03a1","slug":"goals","fullItemName":"Goals"},{"id":"c4185e18-cda2-5c32-93a0-5c296bd5c060","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f88d0725-e6fd-5377-81c4-23ab93a7caf9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4f840bc1-0fc7-584f-873e-932c373ceada","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1532db75-44de-553a-9f1e-252b405093a2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"36684520-6e5e-55c7-9b20-a4036334ed13","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a51d8911-5c44-5fbe-891f-7a1ce243e2d0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3b0bcedc-02f6-597c-91c1-68ad812ee098","slug":"definition","fullItemName":"Definition"},{"id":"dbf72d8a-9d7c-5237-9ec4-41564c1723a2","slug":"causes","fullItemName":"Causes"},{"id":"27706fc3-d0b2-517c-a4ca-f9c337526f6e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"693a21f1-8661-5aa0-a4ad-4fd293690c1f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a7b667a2-77ed-58ce-85e1-28053b3cbac6","slug":"complications","fullItemName":"Complications"},{"id":"69b0affa-ba11-50c0-b7eb-4164215fff81","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"402635e2-8b5b-510b-8911-de663be26627","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2b9d442-db59-5ce2-8001-f79b47a0d07b","slug":"clinical-presentation","fullItemName":"Clinical presentation"},{"id":"5fefa9cc-3cd1-5fe6-97c9-b95e84cf7790","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"d056845a-158d-5904-925f-c1f2590f7c8c","fullItemName":"Management","slug":"management","subChapters":[{"id":"2f065baa-02b7-57a9-a6f9-036079cc78af","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2fead58-dca1-5103-8ad8-61ea6110cd3e","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0ba4b7a5-9a25-5970-b668-a9c7c4fb38af","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"17d25ace-76d2-5ab6-ac1d-8a1238ea8e09","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"6e2d0756-59aa-5521-b157-730945914705","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f5ecaf87-1d35-5c33-8736-46baa81bda4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9235cf50-84ce-54e7-b840-58aa133fc328","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"592eaa54-938e-528f-ac4e-1f2d1e7bf7b7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"37214d7d-d933-54be-90ef-dc6fabcc7943","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"599ff9f8-a29d-5b76-9429-6e0788baf48f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a58d49de-b64c-5e6e-8c5b-5c60f36f832c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2bc165bd-1fb7-56b2-8b43-476ce2b9c4a2","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b8188aa3-5a20-53fc-9ac5-f1500bcb20ee","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a24a1ba5-f0e6-5531-8a0b-07a772461614","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field f6d922c3-6cbf-48fd-ad13-0230b0c0d4be --><h3>Dose</h3><!-- end field f6d922c3-6cbf-48fd-ad13-0230b0c0d4be -->","summary":"","htmlStringContent":"<!-- begin item 2b3331c0-1ab2-41ad-8478-1bbbf35d5ed2 --><!-- begin field 2550af04-ed99-4055-8bad-6381684f9e8b --><ul><li>Adults and children 8 years of age and over — 250 mg to 500 mg, four times a day for 7 days.</li><li>Children 2–7 years of age — 250 mg, four times a day for 7 days.</li><li>Children 1 month to 1 year of age — 125 mg, four times a day for 7 days.<ul><li>Oral erythromycin is available as 250 mg tablets and capsules, 500 mg capsules, and 125 mg per 5 mL, 250 mg per 5 mL, and 500 mg per 5 mL suspension.</li></ul></li><li>The recommendations on length of antibiotics course are extrapolated from an antibiotics guideline produced by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>], and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>].<ul><li>PHE did not consider the treatment of acute paronychia but for other bacterial skin infections, such as impetigo and cellulitis, they recommend a duration of 7 days for empirical antibiotic treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">PHE, 2017</a>].</li><li>Although PHE do not specifically recommend erythromycin for the treatment of skin infections, the BNF recommend it as an alternative to clarithromycin to treat cellulitis, erysipelas or impetigo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>].</li></ul></li><li>CKS found no randomized controlled trials that studied the effectiveness of antibiotic treatment (or the length of antibiotic course needed) for the treatment of acute paronychia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field 2550af04-ed99-4055-8bad-6381684f9e8b --><!-- end item 2b3331c0-1ab2-41ad-8478-1bbbf35d5ed2 -->","subChapters":[]},{"id":"49bfb081-c777-5016-b1d9-f5040ba7a9bd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c2cb82c9-8ae3-49f6-a3ae-a76a008f043e --><h3>Adverse effects</h3><!-- end field c2cb82c9-8ae3-49f6-a3ae-a76a008f043e -->","summary":"","htmlStringContent":"<!-- begin item 6930ecbc-54b2-4ace-a521-a76a008f01fd --><!-- begin field 774671fc-4164-41b1-96dc-a76a008f043e --><ul><li><strong>The most common adverse effects of erythromycin are gastrointestinal symptoms</strong> such as nausea, vomiting and diarrhoea.<ul><li>Clarithromycin usually has milder gastrointestinal adverse effects and should be considered in people who have had a history of gastrointestinal effects when taking erythromycin.</li></ul></li><li><strong>Less common adverse effects include:</strong><ul><li>Cholestatic jaundice.</li><li>Hepatotoxicity.</li><li>Rash.</li><li>Antibiotic-associated colitis.</li><li>Arrhythmias.</li><li>Pancreatitis.</li><li>QT interval prolongation.</li><li>Stevens-Johnson syndrome and toxic epidermal necrolysis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>]</p><!-- end field 774671fc-4164-41b1-96dc-a76a008f043e --><!-- end item 6930ecbc-54b2-4ace-a521-a76a008f01fd -->","subChapters":[]},{"id":"5119a054-60a6-5bf1-8d16-899719644a3a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8afdef6a-4fd0-4e42-b3b9-a76a008f3ce1 --><h3>Contraindications and cautions</h3><!-- end field 8afdef6a-4fd0-4e42-b3b9-a76a008f3ce1 -->","summary":"","htmlStringContent":"<!-- begin item 364e7861-9a70-4d99-87e0-a76a008f2c84 --><!-- begin field 59e10ae8-e4d9-40d7-8da1-a76a008f3ce1 --><ul><li><strong>Do not prescribe erythromycin to people with:</strong><ul><li>Porphyria or a known hypersensitivity to erythromycin.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution in people with:</strong><ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. Hepatic dysfunction including raised liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with this drug.</li><li>Renal impairment — give a maximum of 1.5 g daily in severe renal impairment due to the risk of ototoxicity.</li><li>Myasthenia gravis — macrolide antibiotics may aggravate the weakness of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">MHRA, 2020</a>]</p><!-- end field 59e10ae8-e4d9-40d7-8da1-a76a008f3ce1 --><!-- end item 364e7861-9a70-4d99-87e0-a76a008f2c84 -->","subChapters":[]},{"id":"a328351c-c640-58fc-8a15-583b85412160","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5c50b7e8-262f-4d5e-9b91-a76a008f799a --><h3>Drug interactions</h3><!-- end field 5c50b7e8-262f-4d5e-9b91-a76a008f799a -->","summary":"","htmlStringContent":"<!-- begin item 3ed664a8-cc67-42bd-9108-a76a008f77ab --><!-- begin field 3d1aa880-1dad-469c-a426-a76a008f799a --><p><strong>Multiple interactions exist between erythromycin and other drugs. </strong>The following is not an exhaustive list.</p><p><strong>Drug interactions with erythromycin include:</strong></p><ul><li><strong>Cimetidine </strong>— may inhibit the metabolism of erythromycin, leading to an increased plasma concentration. Reversible hearing loss has been reported.</li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of CCB-related toxicity and adverse effects such as hypotension and QT prolongation, caution is advised with the concurrent use of macrolides and CCBs (such as verapamil, felodipine, nifedipine, amlodipine and diltiazem). Doses of CCBs (particularly verapamil and felodipine) may need to be reduced. The combination of lercanidipine and erythromycin is contraindicated. </li><li><strong>Carbamazepine </strong>— avoid concurrent use unless close monitoring of carbamazepine levels and suitable dose reductions can be carried out.  Toxicity can occur within 24 hours. Carbamazepine toxicity may present as dizziness, diplopia, ataxia and confusion.</li><li><strong>Colchicine </strong>— suspend or reduce the dose of colchicine. Avoid concurrent use in patients with renal or hepatic impairment. Colchicine toxicity has been reported following concomitant use with erythromycin.</li><li><strong>Corticosteroids </strong>— erythromycin may inhibit metabolism of corticosteroids and potentiate their effects.</li><li><strong>Drugs that prolong the QT interval </strong>— if possible, avoid giving erythromycin to a person who is already taking a drug that can potentially prolong the QT interval, such as:<ul><li>Antiarrhythmics (such as amiodarone).</li><li>Antipsychotics (such as amisulpride and haloperidol).</li><li>Tricyclic antidepressants (such as clomipramine).</li><li>Note that concomitant administration of erythromycin and any of the following drugs is contraindicated:<ul><li>Astemizole.</li><li>Cisapride.</li><li>Pimozide.</li><li>Terfenadine.</li><li>Mizolastine.</li><li>Amisulpride.</li><li>Domperidone.</li></ul></li></ul></li><li><strong>Ergotamine or dihydroergotamine </strong>— avoid concomitant use as clarithromycin may increase plasma concentration of ergotamine, resulting in toxicity.</li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not </em>required during or after courses of erythromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if erythromycin is taken with atorvastatin or simvastatin.<ul><li><strong>For simvastatin </strong>— do not prescribe erythromycin to a person taking simvastatin, as simvastatin is extensively metabolised by CYP3A4. </li><li><strong>For atorvastatin </strong>— avoid concurrent use with erythromycin as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, consider temporarily stopping atorvastatin, and advise the person to report any muscle pain, tenderness, or weakness.</li><li><strong>Other statins </strong>— clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. However, caution is recommended for concurrent use of erythromycin and pravastatin.  Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with erythromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— consider using clarithromycin (in preference to erythromycin) as clarithromycin normally causes only minimal, or no increase in theophylline levels.<ul><li>Concurrent use of erythromycin with high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. If used together, monitor theophylline levels after 48 hours and if toxicity is suspected, reduce the dose of theophylline. Signs of theophylline toxicity include tremor, nausea and headache.</li><li>Concurrent treatment may also result in a significant decrease in erythromycin serum concentrations, leading to sub-therapeutic concentrations of erythromycin.</li></ul></li><li><strong>Triazolobenzodiazepines </strong>— caution is recommended for the concurrent use of erythromycin and triazolobenzodiazepines, such as triazolam and midazolam.  Erythromycin inhibits metabolism, which may lead to increased sedation.</li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— monitor the international normalized ratio (INR) within 3 days of starting erythromycin when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. There are reports of increased INR and prothrombin times. Erythromycin may enhance the effect of warfarin; this is an established but unpredictable interaction.</li><li><strong>Zopiclone </strong>— caution is recommended for the concurrent use of zopiclone and erythromycin as erythromycin has been reported to decrease the clearance of zopiclone leading to an increased effect.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/paronychia-acute/references/\">MHRA, 2020</a>]</p><!-- end field 3d1aa880-1dad-469c-a426-a76a008f799a --><!-- end item 3ed664a8-cc67-42bd-9108-a76a008f77ab -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}